Mesenchymal Stem Cell-Derived Extracellular Vesicles: Hype or Hope for Skeletal Muscle Anti-Frailty

Steadily rising population ageing is a global demographic trend due to the advancement of new treatments and technologies in the medical field. This trend also indicates an increasing prevalence of age-associated diseases, such as loss of muscle mass (sarcopenia), which tends to afflict the older po...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-04, Vol.24 (9), p.7833
Main Authors: Mahindran, Elancheleyen, Wan Kamarul Zaman, Wan Safwani, Ahmad Amin Noordin, Khairul Bariah, Tan, Yuen-Fen, Nordin, Fazlina
Format: Article
Language:English
Subjects:
Age
ageing
Aging
Angiogenesis
Apoptosis
Cell growth
Chronic illnesses
Chronic obstructive pulmonary disease
Clinical trials
Enzymes
Extracellular Vesicles
Frailty
Frailty - therapy
Health care
Humans
Kidney diseases
Kinases
Lipids
mesenchymal stem cell
Mesenchymal Stem Cells
MicroRNAs
Microscopy
Mortality
Muscle, Skeletal
Muscles
Musculoskeletal system
Older people
Oxidative stress
Proteins
Quality of Life
Review
Sarcopenia
Sarcopenia - therapy
Signs and symptoms
Skeletal muscle
Stem cell transplantation
Stem cells
Transcription factors
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Steadily rising population ageing is a global demographic trend due to the advancement of new treatments and technologies in the medical field. This trend also indicates an increasing prevalence of age-associated diseases, such as loss of muscle mass (sarcopenia), which tends to afflict the older population. The deterioration in muscle function can cause severe disability and seriously affects a patient's quality of life. Currently, there is no treatment to prevent and reverse age-related skeletal muscle ageing frailty. Existing interventions mainly slow down and control the signs and symptoms. Mesenchymal stem cell-derived extracellular vesicle (MSC-EV) therapy is a promising approach to attenuate age-related skeletal muscle ageing frailty. However, more studies, especially large-scale randomised clinical trials need to be done in order to determine the adequacy of MSC-EV therapy in treating age-related skeletal muscle ageing frailty. This review compiles the present knowledge of the causes and changes regarding skeletal muscle ageing frailty and the potential of MSC-EV transplantation as a regenerative therapy for age-related skeletal muscle ageing frailty and its clinical trials.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24097833